COMMUNIQUÉS West-GlobeNewswire

Southern Pain and Spine Specialists Announces Dr. Ammar Alamarie, MD Named Castle Connolly Top Doctor for Pain Management in 2025 for Second Consecutive Year
13/01/2026
Dr. Ammar Alamarie’s second consecutive Castle Connolly Top Doctor honor for Pain Management, recognizing his clinical excellence, leadership, and compassionate, innovative patient-centered care nationwide. Matthews, NC [...]
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire
13/01/2026
Exclusive U.S. Distribution Partnership with Enlight Medical Ltd. Enables Kaneka Medical America LLC to Bring Novel Neurovascular Guidewire Technology to the U.S. Market NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
13/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
13/01/2026
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
13/01/2026
SARASOTA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility [...]
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
13/01/2026
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - [...]
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
13/01/2026
Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period. Received record multi-system order in the fourth quarter from an [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
13/01/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 janv. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
13/01/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 13, 2026 (GLOBE NEWSWIRE [...]
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
13/01/2026
Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectively [...]
Dentsply Sirona and Benco Dental Announce Expanded Partnership to Include Dental Technology Solutions
13/01/2026
Benco Dental will offer Dentsply Sirona’s full portfolio of dental technology solutions, in addition to the consumables portfolio. Expanding the decades-long relationship reflects a shared vision to advance connected [...]
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
13/01/2026
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the [...]
Aqua free enters the B2C market with “Shower2go”: a portable travel shower for safer showering on the go – helping to reduce exposure to Legionella
13/01/2026
Hamburg, 12.01.2025 – Aqua free , a leading European provider of drinking-water hygiene solutions, is launching Shower2go, a portable travel shower for consumers. Designed for hotels, holiday rentals, campsite washrooms [...]
Synfini Assessed ‘Awardable’ for DARPA ERIS Marketplace
13/01/2026
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Synfini , a leading provider of the industry’s most innovative Agile AI Foundry for drug discovery, today announced that it has achieved “Awardable” status through [...]
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
13/01/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 13, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
13/01/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2026 – GENFIT (Euronext: GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2025
13/01/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025
13/01/2026
Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
La FDA américaine accorde la désignation « Breakthrough Therapy » à l’IPN60340 (ICT01) d’Ipsen dans la leucémie myéloïde aiguë de première ligne chez les patients inéligibles à une chimiothérapie intensive
13/01/2026
La désignation « Breakthrough Therapy » a été accordée pour la thérapie expérimentale IPN60340 en association avec le vénétoclax et l’azacitidine dans la leucémie myéloïde aiguë de première ligne chez les patients [...]

Pages